Low Dose Atropine for Symptomatic Vitreous Floaters
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to identify a potential pharmacologic option by assessing
whether 0.01% atropine may be effective for treating bothersome floaters as measured by
scores on a modified NEI VFQ-25.